Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Company Directory
Abbott Laboratories Medical Diagnostics Products
104 Windsor Center Drive
East Windsor
NJ 08520
USA
[t] 001 847 937 1237
Abbott is a global, broad-based health care company that develops, manufactures and markets pharmaceuticals and medical products, including nutritionals, medical devices and diagnostics.
Abbott to develop rapid molecular test with Genetics Laboratory
06 March, 2012
Abbott is collaborating with Genetics Laboratory on the development of a molecular diagnostic test that will be designed to rapidly detect microorganisms that cause orthopaedic infections.
Utah Department of Health participates in biopreparedness evaluation project
19 April, 2010
Utah Department of Health (UDH) is one of five sites in the USA to participate in Abbott's new PLEX-ID Biopreparedness Evaluation Program (BPEP), which involves Abbott, the Association of Public Health Laboratories (APHL) and five state public health labs.
Abbott acquires STARLIMS Technologies to broaden LIMS portfolio
24 March, 2010
Abbott completes its $123 million acquisition of STARLIMS Technologies, a leader in laboratory information management systems.
Abbott partners GSK to develop a molecular diagnostic test for skin cancer
03 March, 2010
Abbott enters into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.
Abbott submits human epididymis protein 4 (HE4) assay for 510(k) clearance
09 February, 2010
A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the USA from Abbott.
Abbott submits new HIV test to FDA for premarket approval
26 January, 2010
Abbott submits a Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to the US Food and Drug Administration (FDA) for expedited review.
New diagnostic tool determines whether a pelvic mass is benign or malignant
15 January, 2010
A new diagnostic tool that can aid in determining the risk of whether a pelvic mass is benign or malignant is now available in Europe.
Abbott prepares to acquire STARLIMS Technologies
15 December, 2009
Abbott announces a definitive agreement to acquire STARLIMS Technologies, a leading provider of laboratory information management systems, for approximately $123 million in cash.
Abbott and BG Medicine develop biomarker for heart failure test
17 November, 2009
Abbott and BG Medicine agrees a development and commercialization deal for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure.
Fully automated HIV blood screening approval from FDA
22 September, 2009
The US Food and Drug Administration has approved the Prism HIV O Plus test from Abbott for fully automated laboratory screening of donor blood and plasma
WSJ technology Innovation Award for Abbott
17 September, 2009
The Ibis T5000 Biosensor system from Abbott has been recognised by the Wall Street Journal with the Gold prize in the Technology Innovation awards
Abbot once again in the Dow Jones Sustainability Index
07 September, 2009
Corporate Governance, labour practices and climate change mitigation all contributed to Abbot reaching the Dow Jones Sustainability Index for the 5th year running at both the American and Global level
Research network recommends Abbott RealTime viral load test for NIH trials
08 May, 2009
The Abbott RealTime HIV-1 Assay and Abbott m2000 System are being recommended as a standard protocol for viral load testing in HIV/AIDS clinical trials sponsored by the National Institutes of Health (NIH).
Abbott receives 510(k) clearance for new compact haematology instrument
11 February, 2009
Abbott has received 510(k) clearance from the US Food and Drug Administration (FDA) for its new, compact haematology instrument, CELL-DYN Emerald.
New study highlights the impact of point-of-care testing on chest pain patients
19 August, 2008
Patient side point-of-care testing enables doctors to make decisions on patients presenting with chest pain up to 20 minutes faster than those whose lab tests are evaluated by a standard lab, according to a the first-ever randomized controlled clinical trial that directly evaluated the impact of patient side point-of-care testing on 2,000 patients with chest pain, or possible acute coronary syndrome (ACS), on the length of stay in the emergency department (ED).
Blood tests help anti-rejection drugs in kidney transplant patients
31 July, 2008
Research presented at the American Association for Clinical Chemistry (AACC) annual meeting sows that the ability of blood tests to precisely measure low doses of anti-rejection drugs in kidney transplant patients may make a significant difference in assuring long-term viability and survival.
Abbott reveals recipients of the Labs Are Vital instrument donation programme
31 July, 2008
Abbott has announced the recipients of the Labs Are Vital instrument donation programme at the American Association of Clinical Chemistry (AACC) Annual Meeting.
Researchers develop new diagnostic marker for early detection of acute kidney injury
30 July, 2008
Researchers have developed a new diagnostic marker, called urine NGAL, for early detection of acute kidney injury (AKI) in hospitalised patients can distinguish AKI from other forms of kidney dysfunction and prevent kidney failure.
Abbott unveils new immunochemistry analyser to Architect family
15 April, 2008
Abbott has introduced the Architect i1000SR immunochemistry analyser to expand the company’s Architect family of diagnostics instrument systems for clinical laboratories.
Labs Are Vital programme aims to raise profile of clinical laboratory professionals
04 April, 2008
Clinical laboratory professionals worldwide are supporting a new initiative to raise international awareness of the role played by clinical laboratory professionals in health care and their vital contribution to improve patient outcomes.
First fully automated blood screening test for HTLV-I/HTLV-II receives US FDA approval
22 January, 2008
Abbott has received approval from the US Food and Drug Administration for its fully automated HTLV-I/HTLV-II blood screening test for use on the Abbott Prism instrument.
New real-time PCR Test for a new variant strain of Chlamydia receives CE Mark
21 January, 2008
Abbott has developed a new molecular test capable of detecting a new variant strain of Chlamydia trachomatis found in one in five chlamydia cases in Sweden.
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo